Phase II study of oral L-leucovorin, 120-hour fluorouracil infusion and carboplatin in advanced pancreatic cancer

Marco Colleoni, Patrizia Nelli, Giovanni Vicario, Francesca Pancheri, Gigliola Sgarbossa, Paolo Manente

Research output: Contribution to journalArticle

Abstract

Background: No effective chemotherapy has been developed for patients with metastatic pancreatic cancer. Encouraging results have been reported with the combination of cisplatin and fluorouracil infusion. The aim of the study was to test the activity of oral L-leucovorin, carboplatin and fluorouracil infusion in untreated pancreatic cancer patients. Patients and methods: Patients with advanced pancreatic carcinoma were treated with carboplatin (300 mg/m2 on day 1), L-leucovorin (5 mg/m2 twice a day on days 1-5), and fluorouracil (1,000 mg/m2 as a 120-hr infusion on days 1-5), cycles being repeated every 21 days. Results: Nine patients were included and were assessable for response and side effects. All patients had measurable disease and an ECOG performance status of 0-2. No patient achieved partial remission, 3 had stable disease, and 6 progressive disease. Median time to progression was 2 months (range, 2-8), and median survival was 4 months (range, 3-12). Toxicity consisted of mucositis, diarrhea and neutropenia. Conclusions: Patients with metastatic pancreatic carcinoma do not benefit from this treatment schedule.

Original languageEnglish
Pages (from-to)573-575
Number of pages3
JournalTumori
Volume82
Issue number6
Publication statusPublished - Nov 1996

    Fingerprint

Keywords

  • carboplatin
  • fluorouracil infusion
  • oral levo-leucovorin

ASJC Scopus subject areas

  • Cancer Research

Cite this

Colleoni, M., Nelli, P., Vicario, G., Pancheri, F., Sgarbossa, G., & Manente, P. (1996). Phase II study of oral L-leucovorin, 120-hour fluorouracil infusion and carboplatin in advanced pancreatic cancer. Tumori, 82(6), 573-575.